Table 3 Effects of treatment redosing

From: Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice

Treatment

n

Growth curves, V(t)

r

Tumor doubling time ( d)

Growth delay ( d)

30-day survival

PBS

11

ln(V)=0.10t+5.50

0.99

6.6 (6.4–6.9)

0 (0–2.0)

0.0

PBS+2 Gy (2X)

4

ln(V)=0.05t+5.76

0.91

14.5 (13.7–15.3)*

10.5 (9.1–12.0)*

0.25

VNP pRT+2 Gy (2X)

4

V=0.07t2–16.67t+245.45

0.92

NA

30.3 (26.6–34.1)*,†

1.0*,†

  1. Data are listed as means with their 95% confidence intervals in parentheses. Treatments of Balb/c mice with 21-day 4T1/red tumors were performed using intravenous injections of PBS (control) or 100 000 cfu g−1 VNP20009 pRecA_TRAIL (VNP pRT). Treatment dosing was at days 0 and 6, with 2 Gy irradiation at days 2 and 8. Regression growth curves summarise volume (V, mm3) dependence on time (t, days) from initial treatment, with correlation coefficients indicated by r. Tumor doubling time was derived from exponential growth curves. Growth delay was determined by assessing the time interval to 1000 mm3 compared with the PBS control. Note that for comparison, the PBS control data are repeated from Table 1.
  2. *P<0.05 compared with PBS.
  3. †P<0.05 compared with PBS and 2 Gy (2 × ) irradiation.
Back to article page